ABOUT US The Medicinal Organic Chemistry Group is a research group at the Research Institute for Medicines (iMed) focused on the development of new scaffolds to target diseases such as cancer, malaria and tuberculosis. MedOrgChemGroup
The Medicinal Organic Chemistry (MOC) Group is delighted to celebrate an important milestone as Oliviero Cini successfully defended his PhD thesis, co-supervised by Professor Maria M. M. Santos. Over the course of his PhD journey, Oliviero has demonstrated outstanding dedication, scientific curiosity, and perseverance. His research has made valuable contributions to our group's scientific endeavors, and his commitment to advancing medicinal chemistry has been truly inspiring.
We are delighted to announce the publication of our latest review article, "Drugging p53 mutants: Recent advances using small-molecule modulation strategies," in the European Journal of Medicinal Chemistry. This review provides a comprehensive overview of recent advances in targeting mutant p53 proteins through small-molecule modulation strategies. It explores the molecular mechanisms behind these approaches, highlights the key discoveries that have shaped the field, and disc
The Medicinal Organic Chemistry (MOC) Group is proud to celebrate a remarkable milestone as Israa Al jnadi successfully defended her PhD thesis under the supervision of Professor Alexandra Paulo. Throughout her PhD journey, Israa has demonstrated exceptional dedication, scientific excellence, and resilience. Her commitment to advancing research and her invaluable contributions to our group have left a lasting impact on both our science and our team. As Israa embarks on the ne
